VANI

Vivani Medical, Inc. (VANI) - Q2 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2026. Vivani Medical, Inc. is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal technology. The company operates two segments: the Biopharm Division (primary focus) and the Neurostimulation Division (Cortigent), which is in the process of being spun off or merged with ClearOne, Inc.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased slightly year-over-year for the six-month period, from $13.45 million in 2025 to $13.15 million in 2026, driven by a reduction in operating expenses.
• Operating Expenses: Total operating expenses decreased by $0.20 million (1.4%) year-over-year. Research and Development (R&D) expenses remained flat at approximately $9.0 million, while General and Administrative (G&A) expenses decreased by $0.18 million.
• Other Income: Other income, net, increased to $0.67 million for the six months ended June 30, 2026, compared to $0.57 million in the prior year. This increase was primarily due to a $0.335 million gain from the derecognition of a legacy contract liability related to the discontinued Argus II retinal prosthesis program.
• Capital Raising: The company raised significant capital in the first half of 2026, generating $15.55 million in net cash from financing activities. This included proceeds from a Registered Direct Offering ($2.2 million) and Private Sales Transactions ($11.6 million).

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Existing cash is estimated to fund operations only through the second quarter of 2027. The company requires additional financing to continue operations beyond this date.
• Cortigent Transaction: On July 1, 2026, Vivani entered into a merger agreement to merge its Neurostimulation subsidiary, Cortigent, with ClearOne, Inc. Vivani expects to receive 12.5 million shares of ClearOne stock. ClearOne is pursuing $10-$15 million in financing concurrent with the merger. If this transaction fails to close by Q3 2026, Vivani may need to discontinue Cortigent's operations to preserve liquidity.
• Clinical Progress: Dosing was completed for all participants in the SLIM-1 trial of NPM-139 (semaglutide implant) in August 2026. Topline data is anticipated in November 2026.
• Legal Contingencies:
  • Pixium Vision SA: Pending appeal in the Paris Court of Appeal regarding a terminated MOU. A prior judgment ordered Vivani to pay approximately €1.55 million net. Vivani's appeal was struck out for failure to enforce the judgment, requiring reinstatement within two years.
  • Oppenheimer & Co. Inc.: Litigation seeking $1.625 million in damages regarding a placement agent agreement. Discovery is commencing on the remaining breach of contract claim.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the "second quarter of 2027" liquidity estimate and the status of any new financing efforts post-filing.
• Cortigent Merger Status: Confirm the closing conditions and timeline for the Cortigent/ClearOne merger, as failure to close impacts Vivani's liquidity strategy.
• SLIM-1 Trial Data: Monitor the release of topline data for the NPM-139 trial in November 2026, which is critical for future valuation and funding.
• Legal Exposure: Review the status of the Pixium appeal reinstatement and the Oppenheimer litigation discovery process to assess potential cash outflows.
• Dilution: Note the significant share issuance in H1 2026 (approx. 13 million shares issued) and its impact on per-share value.